Wang Jing-Jia, Zhuang Zhen-Huang, Yu Can-Qing, Wang Wen-Yao, Wang Wen-Xiu, Zhang Kuo, Meng Xiang-Bin, Gao Jun, Tian Jian, Zheng Ji-Lin, Yang Jie, Huang Tao, Shao Chun-Li, Tang Yi-Da
Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China.
J Geriatr Cardiol. 2022 Jan 28;19(1):61-70. doi: 10.11909/j.issn.1671-5411.2022.01.004.
Growing evidence have demonstrated that thyroid hormones have been involved in the processes of cardiovascular metabolism. However, the causal relationship of thyroid function and cardiometabolic health remains partly unknown.
The Mendelian randomization (MR) was used to test genetic, potentially causal relationships between instrumental variables and cardiometabolic traits. Genetic variants of free thyroxine (FT4) and thyrotropin (TSH) levels within the reference range were used as instrumental variables. Data for genetic associations with cardiometabolic diseases were acquired from the genome-wide association studies of the FinnGen, CARDIoGRAM and CARDIoGRAMplusC4D, CHARGE, and MEGASTROKE. This study was conducted using summary statistic data from large, previously described cohorts. Association between thyroid function and essential hypertension (EHTN), secondary hypertension (SHTN), hyperlipidemia (HPL), type 2 diabetes mellitus (T2DM), ischemic heart disease (IHD), myocardial infarction (MI), heart failure (HF), pulmonary heart disease (PHD), stroke, and non-rheumatic valve disease (NRVD) were examined.
Genetically predicted FT4 levels were associated with SHTN (odds ratio = 0.48; 95% CI = 0.04-0.82, = 0.027), HPL (odds ratio = 0.67; 95% CI = 0.18-0.88, = 0.023), T2DM (odds ratio = 0.80; 95% CI = 0.42-0.86, = 0.005), IHD (odds ratio = 0.85; 95% CI = 0.49-0.98, = 0.039), NRVD (odds ratio = 0.75; 95% CI = 0.27-0.97, = 0.039). Additionally, genetically predicted TSH levels were associated with HF (odds ratio = 0.82; 95% CI = 0.68-0.99, = 0.042), PHD (odds ratio = 0.75; 95% CI = 0.32-0.82, = 0.006), stroke (odds ratio = 0.95; 95% CI = 0.81-0.97, = 0.007). However, genetically predicted thyroid function traits were not associated with EHTN and MI.
Our study suggests FT4 and TSH are associated with cardiometabolic diseases, underscoring the importance of the pituitary-thyroid-cardiac axis in cardiometabolic health susceptibility.
越来越多的证据表明甲状腺激素参与了心血管代谢过程。然而,甲状腺功能与心脏代谢健康之间的因果关系仍部分未知。
采用孟德尔随机化(MR)方法来检验工具变量与心脏代谢特征之间的遗传、潜在因果关系。参考范围内的游离甲状腺素(FT4)和促甲状腺激素(TSH)水平的基因变异被用作工具变量。与心脏代谢疾病的基因关联数据来自芬兰基因库、CARDIoGRAM和CARDIoGRAMplusC4D、CHARGE以及MEGASTROKE的全基因组关联研究。本研究使用了来自大型、先前描述的队列的汇总统计数据。研究了甲状腺功能与原发性高血压(EHTN)、继发性高血压(SHTN)、高脂血症(HPL)、2型糖尿病(T2DM)、缺血性心脏病(IHD)、心肌梗死(MI)、心力衰竭(HF)、肺心病(PHD)、中风和非风湿性瓣膜病(NRVD)之间的关联。
基因预测的FT4水平与SHTN(优势比=0.48;95%置信区间=0.04 - 0.82,P = 0.027)、HPL(优势比=0.67;95%置信区间=0.18 - 0.88,P = 0.023)、T2DM(优势比=0.80;95%置信区间=0.42 - 0.86,P = 0.005)、IHD(优势比=0.85;95%置信区间=0.49 - 0.98,P = 0.039)、NRVD(优势比=0.75;95%置信区间=0.27 - 0.97,P = 0.039)相关。此外,基因预测的TSH水平与HF(优势比=0.82;95%置信区间=0.68 - 0.99,P = 0.042)、PHD(优势比=0.75;95%置信区间=0.32 - 0.82,P = 0.006)、中风(优势比=0.95;95%置信区间=0.81 - 0.97,P = 0.007)相关。然而,基因预测的甲状腺功能特征与EHTN和MI无关。
我们的研究表明FT4和TSH与心脏代谢疾病相关,强调了垂体 - 甲状腺 - 心脏轴在心脏代谢健康易感性中的重要性。